Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interaction between valproate and meropenem: a retrospective study.

Isabel Spriet1, Jo Goyens, Wouter Meersseman

  • 1University Hospital Gasthuisberg, Leuven, Belgium. Isabel.Spriet@uz.kuleuven.be

The Annals of Pharmacotherapy
|July 5, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clofazimine use for nontuberculous mycobacterial infections: 10-year experience in Belgium.

BMC pulmonary medicine·2026
Same author

Impact of Concomitant Metamizole Treatment on the Exposure of Mould-Active Triazoles.

Mycoses·2026
Same author

Precision Dosing of Vancomycin: A Systematic Review of Population Pharmacokinetics Models and Comparative Evaluation of Software Tools.

Clinical pharmacokinetics·2026
Same author

Histological proof of pulmonary herpesvirus presence in patients with COVID-19- or influenza-related ARDS.

Critical care (London, England)·2026
Same author

Impact Assessment of the Allergy Fact Checker, a Clinical Decision Support Tool for Noninvasive Beta-Lactam Antibiotic Allergy Label Delabeling: Protocol for a Multicenter Crossover Cluster-Controlled Study.

JMIR research protocols·2026
Same author

Clinical Outcome Associated With Beta-Lactam Allergy Labels in Hospitalized Patients in Belgium.

Clinical and translational allergy·2026

Concurrent use of meropenem and valproate causes a significant 66% drop in valproate levels within 24 hours, potentially leading to seizure relapse. Clinicians should avoid co-administering these critical care drugs.

Area of Science:

  • Pharmacology
  • Critical Care Medicine
  • Neuroscience

Background:

  • Valproate and meropenem are essential in intensive care for seizures and infections.
  • Case reports indicate a significant drug interaction when these are used together.
  • This interaction can drastically reduce valproate levels and trigger seizure recurrence.

Purpose of the Study:

  • To assess the impact of concurrent meropenem and valproate administration on hospitalized patients.
  • To evaluate the effect of this drug interaction on seizure activity and electroencephalogram (EEG) readings.
  • To determine the clinical relevance and contributing factors of the valproate-meropenem interaction.

Main Methods:

  • A retrospective analysis of 39 patients over 18 months receiving both drugs.

Related Experiment Videos

  • Monitoring of valproate plasma concentrations and seizure activity.
  • Calculation of Drug Interaction Probability Scale (DIPS) scores to assess causality.

    • Main Results:

    • All 39 patients experienced a pharmacokinetic interaction, with a 66% average decrease in valproate levels within 24 hours.
    • Clinical relevance was assessed in 20 patients; the interaction was probable in 16 and possible in 4.
    • Electroclinical deterioration occurred in 11 patients (55% of those assessed for clinical relevance).

    Conclusions:

    • The pharmacokinetic interaction between valproate and meropenem is consistently observed, reducing valproate levels by 66% within 24 hours.
    • This interaction is clinically significant, contributing to neurological deterioration in over half of the assessed patients.
    • To prevent adverse neurological outcomes, concurrent administration of meropenem and valproate should be avoided.